ARKRAY USA And Mellitus Health Announce Licensing Agreement

Tuesday, January 30, 2018 Medico Legal News
Email Print This Page Comment bookmark
Font : A-A+

Diabetes Healthcare Leader Licenses Comprehensive Insulin Titration Software for Clinicians

LOS ANGELES and MINNEAPOLIS, Jan. 30, 2018 /PRNewswire/ -- ARKRAY USA,

Inc., a leader in diabetes care products, has entered into a license agreement with Mellitus Health, Inc. (formerly Insulin Algorithms, Inc.), the developer of Insulin Insights™, the first FDA-cleared and CE-registered clinician decision-support tool for titrating all five types of insulin and all insulin combinations. The agreement will allow ARKRAY to integrate Insulin Insights into ARKRAY's suite of diabetes care products.

"Mellitus Health's software unlocks the value of glucose monitor data to make life easier for clinicians, save money for insurers and managed care providers, and—most importantly—improve health outcomes for patients using our GLUCOCARD® and ReliOn™ branded blood glucose meters," said Jonathan Chapman, President of ARKRAY USA. "Our partnership with Mellitus Health has the potential to significantly improve diabetes clinical care."

Insulin Insights uses proprietary algorithms proven to help clinicians lower HbA1c and maintain proper blood sugar levels by providing fast, detailed analyses and titration recommendations for optimized insulin therapy. [i]The software is compatible with any blood glucose monitoring system and works with all brands of insulin and the more than 125 insulin regimens endorsed by the American Diabetes Association.

"We designed Insulin Insights to address the diabetes care gap, which is the failure of health care systems to meet the clinical needs of the growing diabetic population," said Josh Davidson, CEO of Mellitus Health. "Ninety percent of diabetics are treated by primary care physicians because of the massive shortage of endocrinologists. Insulin Insights mitigates this problem by giving these and other clinicians, including nurses and physician assistants, the ability to provide the regular insulin dose adjustments needed to maintain blood sugar control. We look forward to working with ARKRAY as they share our vision of improving the care of the diabetic patient by creating an end-to-end solution from patient to clinician."

About ARKRAY USA, Inc.ARKRAY USA, Inc. is a division of ARKRAY, a global leader in diabetes care with headquarters in Kyoto, Japan. For more than half a century, ARKRAY has pioneered products to ensure that people who have diabetes - and the health professionals who care for them - can better manage the condition. ARKRAY currently does business in more than 80 countries worldwide and is the market leader in diabetes management in the long-term care market in the U.S. The Company has a long history of developing cutting edge technology such as the first portable glucose analyzer available in the United States; the first HbA1c analyzer; and the first hand-held blood glucose meter. For more information, visit

About Mellitus Health, Inc.Mellitus Health is a healthcare technology company headquartered in Los Angeles, CA. Its first product, Insulin Insights, received FDA clearance in 2017. Insulin Insights helps clinicians analyze blood-glucose monitor data and adjust a patient's insulin regimen in seconds, using algorithms that are clinically proven to lower HbA1c levels. It is the only comprehensive dosing solution for all patients and all insulin regimens. Insulin Insights uses algorithms developed over 35 years by Mayer B. Davidson, MD, a former president of the ADA and the recipient of its 2016 Outstanding Physician-Clinician Award. Thousands of clinicians have been trained in Dr. Davidson's insulin dosing method, and his algorithms have been used for decades to manage blood sugars in some of the most challenging patient populations. For more information, please visit

[i] Integrating Nurse-Directed Diabetes Management Into a Primary Care Setting, Mayer B. Davidson, MD; Maria Blanco-Castellanos, RN; and Petra Duran, BS (Source)


Cision View original content:


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store